Imagine battling obesity with a powerful drug like Wegovy, only to quit because of relentless nausea and vomiting – a frustrating reality for many. But what if there was a game-changer that could prevent these side effects and keep patients on track? That's the exciting potential unveiled by Vanda Pharmaceuticals' recent announcement on their drug Tradipitant. And this is the part most people miss: how this breakthrough could transform a booming $50 billion-plus market, making weight loss treatments more accessible and effective than ever before.
Vanda Pharmaceuticals, a top biopharmaceutical firm dedicated to creating and marketing groundbreaking treatments, has shared encouraging top-line findings from their randomized controlled clinical trial (VP-VLY-686-2601). This study tested Tradipitant, an oral medication that blocks neurokinin-1 (NK-1) receptors, in its ability to ward off nausea and vomiting triggered by GLP-1 receptor agonists like Wegovy in adults who are overweight or obese. For beginners, GLP-1 agonists are drugs that imitate a natural hormone in your body, helping to curb appetite and promote weight loss by making you feel fuller longer.
In this trial, participants received either Tradipitant or a placebo before getting a 1 mg dose of Wegovy – a level that typically requires nine weeks of gradual increases under standard prescribing rules. The results were impressive: Tradipitant achieved its main goal, with just 29.3% of those on the drug (17 out of 58) experiencing vomiting, compared to 58.6% on placebo (34 out of 58), marking a 50% relative drop (p=0.0016). It also hit a crucial secondary target, where only 22.4% in the Tradipitant group (13 out of 58) had both vomiting and moderate to severe nausea, versus 48.3% on placebo (28 out of 58) (p=0.0039). Nausea severity was rated on a scale from 0 to 5, with 3 or higher meaning moderate or worse.
And here's where it gets controversial: these side effects are behind 30-50% of real-world dropouts from GLP-1 treatments before reaching full doses. But what if adding Tradipitant could flip the script, boosting adherence and letting more folks reap the benefits like significant weight loss (often 15-20% with consistent use) and lower risks of issues such as diabetes progression or heart events? Critics might argue that introducing another drug adds complexity and cost, potentially deterring patients or insurers – is this a necessary innovation or just another pill to swallow?
Tradipitant showed a solid safety record, matching past studies with no unexpected issues popping up.
Dr. Mihael H. Polymeropoulos, Vanda's President and CEO, commented: 'These outcomes highlight Tradipitant's promise in tackling GLP-1-related nausea and vomiting, major reasons for the 30-50% real-world quit rates before hitting therapeutic levels. By cutting down on these symptoms, Tradipitant could dramatically enhance adherence, helping more individuals unlock the complete benefits of GLP-1 drugs.'
Interestingly, Tradipitant's success echoes its performance in motion sickness trials, where it slashed vomiting by over 50% in studies involving more than 800 people. This positions it as a potential game-changer in the fast-growing GLP-1 market, projected to exceed $50 billion in the first nine months of 2025.
Premature stops due to stomach troubles aren't just a hassle for patients – they lead to wasted efforts, with folks missing out on key health gains and payers footing the bill for unused meds plus extra expenses from ongoing obesity, like hospital stays. For example, think of someone investing time and money into a treatment plan only to abandon it midway, leaving their health goals unmet and adding financial strain on healthcare systems.
The trial, a randomized, double-blind, and placebo-controlled setup, involved 116 healthy adults who were overweight or obese (with a BMI between 25 and 40 kg/m²) and new to GLP-1 agonists. They got the 1 mg Wegovy shot after a week of pre-treatment with either 85 mg Tradipitant twice daily or placebo, then another week of the same treatment. Daily self-reports tracked the outcomes.
Vanda plans to chart a streamlined path for regulatory green light. They anticipate kicking off a Phase III program in the first half of 2026, cementing Tradipitant's role as a vital add-on for better GLP-1 results.
References:
1. Blue Health Intelligence. (2024, May). Real-world trends in GLP-1 treatment persistence and prescribing for weight management [Issue brief]. Blue Cross Blue Shield Association. https://www.bcbs.com/media/pdf/BHIIssueBriefGLP1Trends.pdf
2. Samuels JM, Ye F, Irlmeier R, Silver H, Srivastava G, Spann M. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes Obes Metab. 2025 Nov;27(11):6200-6209. doi: 10.1111/dom.70004. Epub 2025 Aug 5. PMID: 40762026; PMCID: PMC12515774.
3. Eli Lilly and Company. (2025, October 30). Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance [Press release]. PR Newswire. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd
4. Novo Nordisk A/S. (2025, November 5). Financial results for the third quarter of 2025 [Press release]. Novo Nordisk Investor Relations. https://www.novonordisk.com/investors/financial-results.html
5. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. doi:10.1111/jamanetworkopen.2024.57349
About Tradipitant
Tradipitant, an NK-1 receptor blocker licensed from Eli Lilly and Company, is being developed for conditions like gastroparesis and GLP-1-induced nausea and vomiting. It's also undergoing FDA review for motion sickness, with a target decision date of December 30, 2025.
About Vanda Pharmaceuticals Inc.
Vanda is a global leader in biopharmaceuticals, committed to developing and bringing to market innovative treatments for significant unmet medical needs, ultimately improving patient lives. Learn more at www.vandapharma.com and follow us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, such as those about Tradipitant's potential in the GLP-1 space, its ability to boost adherence and deliver full benefits, estimates on dropout rates and market size/growth, and Vanda's plans for development and Phase III trials. These are not guarantees of future performance and involve risks and uncertainties. Actual outcomes could differ due to factors like Tradipitant's effectiveness in real-world use, adherence improvements, data accuracy, and regulatory successes. Investors should consider Vanda's risks in their latest SEC filings, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, available at www.sec.gov. Vanda disclaims any duty to update these statements, except as legally required.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[emailprotected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[emailprotected]
Follow us on X @vandapharma
SOURCE Vanda Pharmaceuticals Inc.
What do you think – could Tradipitant be the missing piece in weight loss therapy, or might it just complicate things further? Do you support adding preventive meds for side effects, or should drugmakers focus on better formulations from the start? Share your opinions in the comments below and let's discuss!
